Argentum Medical, dba Cura Surgical, a privately held medical device company, announced that its Silverlon Antimicrobial Dressings has received an Innovative Technology contract from Vizient, Inc.
Cura Surgical is honored by this recognition and proud of our Silverlon products that demonstrate unique qualities and differentiators from other antimicrobial dressings on the market.
GENEVA, Ill. (PRWEB)
September 14, 2022
Argentum Medical, dba Cura Surgical, a privately held medical device company, announced that its Silverlon Antimicrobial Dressings has received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country. The contract was based on the recommendation of Silverlon by healthcare clinicians in this category.
Innovative technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology program. Cura Surgical had the privilege to present Silverlon Antimicrobial Dressings at the Vizient Innovative Technology Exchange last September. The exchange offers selected suppliers the unique opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient’s member hospitals and subject matter experts who serve on their supply councils. Each technology showcases how it improves clinical outcomes, enhances safety or drives incremental improvements to health care delivery or business models.
“Our goal is to help healthcare professionals provide the highest level of care for their patients,” states Raul Brizuela, President and CEO of Cura Surgical. “We are honored by this recognition and proud of our products that demonstrate unique qualities and differentiators from other antimicrobial dressings on the market.”
Silverlon’s Innovative Technology recognition by Vizient is further validated by the U.S. Food and Drug Administration’s (FDA) 2021 Breakthrough Device Designation for Silverlon Wound Contact and Burn Contact Dressings. This FDA designation is an exceptional status provided to certain devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, granted to only 206 devices in 2021.
Silverlon dressings contain 50-100 times more pure silver than other silver-impregnated dressings and are backed by published clinical studies in numerous specialties. The unique action of ionic silver makes it an ideal element in an antimicrobial dressing. Originally developed to treat burn and blast injuries for the U.S. military, Silverlon dressings are now used throughout the world by surgeons and other healthcare professionals on surgical wounds, burn, vascular access, circulatory support and in negative pressure wound therapy.
“A product receives this type of contract when it demonstrates a unique quality that differentiates it from other products on the market,” said Kelly Flaharty, senior director of contract process for Vizient. “Our member council determined that Silverlon Antimicrobial Dressings met this standard and recognizes its potential to improve quality outcomes.”
Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents more than $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to health care. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.
About Cura Surgical
Cura Surgical, an Argentum Medical company, pioneered the use of silver-plated nylon. Specializing in the development of innovative products made from silver-plated nylon, the company continues to explore new applications and markets for its Silverlon technology in keeping with its corporate mission to improve clinical outcomes.
###
Share article on social media or email: